Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma

This article belongs to the Special Issue Emerging Non-Canonical Functions and Regulation of p53.The p53 pathway is inactivated in the majority of human cancers. Although this perturbation frequently occurs through the mutation or deletion of p53 itself, there are other mechanisms that can attenuate the pathway and contribute to tumorigenesis. For example, overexpression of important p53 negative regulators, such as murine double minute 2 (MDM2) or murine double minute 4 (MDM4), epigenetic deregulation, or even alterations in TP53 mRNA splicing. In this work, we will review the different mechanisms of p53 pathway inhibition in cancer with special focus on multiple myeloma (MM), the second most common hematological malignancy, with low incidence of p53 mutations/deletions but growing evidence of indirect p53 pathway deregulation. Translational implications for MM and cancer prognosis and treatment are also reviewed.This study was partially supported by the Instituto de Salud Carlos III-Cofinanciación con fondos FEDER (PI16/01074), the Gerencia Regional de Salud, Junta de Castilla y León (1344/A/16) grants, and the INNOCAM-PUS Program (CEI10-1-0010).Peer Reviewe